# Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/schedules-controlled-substances-ethylphenidate-schedule-i/ > **Published:** 2026-03-08T19:44:50-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:09:52-04:00 > **Clinical Summary:** Explore the schedules of controlled substances with focus on ethylphenidate's placement in Schedule I and its regulatory implications. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Regulations.gov PolicySafetyResearch Clinical Perspective The DEA’s placement of ethylphenidate in Schedule I reflects regulatory concern about a novel synthetic compound with stimulant properties and abuse potential, though clinical evidence on this specific agent remains sparse. Ethylphenidate, an active metabolite of methylphenidate prodrugs, emerged in illicit contexts before formal scheduling, highlighting the challenge of regulating designer drugs that may appear in uncontrolled or counterfeit formulations. While this scheduling decision does not directly impact standard methylphenidate prescribing for ADHD, it underscores the need for clinicians to remain vigilant about patients’ access to diverted or counterfeit stimulant medications, which may contain unexpected synthetic analogs. The regulatory approach also reflects broader uncertainty: we have limited human safety or efficacy data on many synthetic derivatives that appear in street supplies, making it difficult to counsel patients who may have encountered these substances. Clinicians should 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Ethylphenidate+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2023-0129-0013) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2023-0129-0013) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Ethylphenidate+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2023-0129-0013) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Regulatory Digest 2026-03-06](https://cedclinic.com/controlled-substances-rescheduling-2026/) - [Regulatory Digest 2026-03-05](https://cedclinic.com/regulatory-cannabis-manufacturing-compliance-2026/) 📰 Source: [https://www.regulations.gov/document/DEA-2023-0129-0013](https://www.regulations.gov/document/DEA-2023-0129-0013) Further Reading Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) Review the regulatory placement of novel synthetic opioids in Schedule I and their clinical implications. [Read More](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://cedclinic.com/scheduling-novel-synthetic-opioids-schedule-i/) Explore the scheduling of emerging synthetic opioids and their impact on [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) and policy. [Learn More](https://cedclinic.com/scheduling-novel-synthetic-opioids-schedule-i/) [The right schedule for marijuana (among other drugs) does not yet exist | Science](https://cedclinic.com/2026-cannabis-schedule-classification-challenges/) An analysis of [drug scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/) challenges including cannabis and synthetic substances in regulatory frameworks. [Discover Insights](https://cedclinic.com/2026-cannabis-schedule-classification-challenges/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).